Thoroughbred Financial Services LLC Sells 1,440 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thoroughbred Financial Services LLC trimmed its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,800 shares of the company’s stock after selling 1,440 shares during the quarter. Thoroughbred Financial Services LLC’s holdings in Teva Pharmaceutical Industries were worth $185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in Teva Pharmaceutical Industries by 705.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after purchasing an additional 507,568 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth approximately $3,000,000. SG Americas Securities LLC grew its stake in shares of Teva Pharmaceutical Industries by 31.7% in the fourth quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock worth $5,689,000 after acquiring an additional 131,043 shares during the period. Wellington Management Group LLP grew its stake in shares of Teva Pharmaceutical Industries by 42.2% in the third quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock worth $3,515,000 after acquiring an additional 102,261 shares during the period. Finally, Gateway Investment Advisers LLC grew its stake in shares of Teva Pharmaceutical Industries by 28.6% in the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after acquiring an additional 9,312 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Piper Sandler reissued an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.22.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $16.76 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $17.13. The company has a market capitalization of $18.79 billion, a P/E ratio of -40.88, a P/E/G ratio of 2.11 and a beta of 1.04. The firm’s 50 day simple moving average is $14.31 and its two-hundred day simple moving average is $12.29.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 9,815 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the transaction, the vice president now owns 9,701 shares of the company’s stock, valued at $127,277.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the sale, the chief accounting officer now owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Eric Drape sold 9,815 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the sale, the vice president now owns 9,701 shares in the company, valued at approximately $127,277.12. The disclosure for this sale can be found here. Insiders have sold 141,900 shares of company stock valued at $2,013,861 over the last 90 days. 0.55% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.